FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1872181102> ?p ?o ?g. }

• W1872181102 endingPage "e0136324" @default.
• W1872181102 startingPage "e0136324" @default.
• W1872181102 abstract "Aim To evaluate the efficacy and safety of bevacizumab in the adjuvant cancer therapy setting within different subset of patients. Methods & Design/ Results PubMed, EMBASE, Cochrane and Clinical trials.gov databases were searched for English language studies of randomized controlled trials comparing bevacizumab and adjuvant therapy with adjuvant therapy alone published from January 1966 to 7th of May 2014. Progression free survival, overall survival, overall response rate, safety and quality of life were analyzed using random- or fixed-effects models according to the PRISMA guidelines. We obtained data from 44 randomized controlled trials (30,828 patients). Combining bevacizumab with different adjuvant therapies resulted in significant improvement of progression free survival (log hazard ratio, 0.87; 95% confidence interval (CI), 0.84–0.89), overall survival (log hazard ratio, 0.96; 95% CI, 0.94–0.98) and overall response rate (relative risk, 1.46; 95% CI: 1.33–1.59) compared to adjuvant therapy alone in all studied tumor types. In subgroup analyses, there were no interactions of bevacizumab with baseline characteristics on progression free survival and overall survival, while overall response rate was influenced by tumor type and bevacizumab dose (p-value: 0.02). Although bevacizumab use resulted in additional expected adverse drug reactions except anemia and fatigue, it was not associated with a significant decline in quality of life. There was a trend towards a higher risk of several side effects in patients treated by high-dose bevacizumab compared to the low-dose e.g. all grade proteinuria (9.24; 95% CI: 6.60–12.94 vs. 2.64; 95% CI: 1.29–5.40). Conclusions Combining bevacizumab with different adjuvant therapies provides a survival benefit across all major subsets of patients, including by tumor type, type of adjuvant therapy, and duration and dose of bevacizumab therapy. Though bevacizumab was associated with increased risks of some adverse drug reactions such as hypertension and bleeding, anemia and fatigue were improved by the addition of bevacizumab." @default.
• W1872181102 created "2016-06-24" @default.
• W1872181102 creator A5018590706 @default.
• W1872181102 creator A5023531951 @default.
• W1872181102 creator A5034375062 @default.
• W1872181102 creator A5040046813 @default.
• W1872181102 creator A5077437482 @default.
• W1872181102 date "2015-09-02" @default.
• W1872181102 modified "2023-10-02" @default.
• W1872181102 title "Efficacy and Safety Assessment of the Addition of Bevacizumab to Adjuvant Therapy Agents in Cancer Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials" @default.
• W1872181102 cites W1521811891 @default.
• W1872181102 cites W1966201413 @default.
• W1872181102 cites W1972328572 @default.
• W1872181102 cites W1974050413 @default.
• W1872181102 cites W1976585485 @default.
• W1872181102 cites W1977379029 @default.
• W1872181102 cites W1990737207 @default.
• W1872181102 cites W2007872832 @default.
• W1872181102 cites W2008142406 @default.
• W1872181102 cites W2012852444 @default.
• W1872181102 cites W2013865180 @default.
• W1872181102 cites W2022254881 @default.
• W1872181102 cites W2048067273 @default.
• W1872181102 cites W2048818094 @default.
• W1872181102 cites W2053083499 @default.
• W1872181102 cites W2057735943 @default.
• W1872181102 cites W2060251426 @default.
• W1872181102 cites W2061416514 @default.
• W1872181102 cites W2080109178 @default.
• W1872181102 cites W2091917093 @default.
• W1872181102 cites W2095704084 @default.
• W1872181102 cites W2098136315 @default.
• W1872181102 cites W2098276344 @default.
• W1872181102 cites W2098499757 @default.
• W1872181102 cites W2099919027 @default.
• W1872181102 cites W2100327051 @default.
• W1872181102 cites W2100669312 @default.
• W1872181102 cites W2100756525 @default.
• W1872181102 cites W2100785570 @default.
• W1872181102 cites W2103563357 @default.
• W1872181102 cites W2104569020 @default.
• W1872181102 cites W2108923852 @default.
• W1872181102 cites W2111053501 @default.
• W1872181102 cites W2111398643 @default.
• W1872181102 cites W2113122060 @default.
• W1872181102 cites W2114159573 @default.
• W1872181102 cites W2115005218 @default.
• W1872181102 cites W2115369775 @default.
• W1872181102 cites W2115898240 @default.
• W1872181102 cites W2122574381 @default.
• W1872181102 cites W2123152662 @default.
• W1872181102 cites W2123679594 @default.
• W1872181102 cites W2125447919 @default.
• W1872181102 cites W2125857654 @default.
• W1872181102 cites W2126275851 @default.
• W1872181102 cites W2128095147 @default.
• W1872181102 cites W2135947389 @default.
• W1872181102 cites W2139248078 @default.
• W1872181102 cites W2143743735 @default.
• W1872181102 cites W2144660856 @default.
• W1872181102 cites W2145708352 @default.
• W1872181102 cites W2145835533 @default.
• W1872181102 cites W2149373064 @default.
• W1872181102 cites W2153982924 @default.
• W1872181102 cites W2153991063 @default.
• W1872181102 cites W2155167083 @default.
• W1872181102 cites W2155338842 @default.
• W1872181102 cites W2157769714 @default.
• W1872181102 cites W2158679766 @default.
• W1872181102 cites W2160373161 @default.
• W1872181102 cites W2161534604 @default.
• W1872181102 cites W2161664263 @default.
• W1872181102 cites W2164363535 @default.
• W1872181102 cites W2165088640 @default.
• W1872181102 cites W2167224460 @default.
• W1872181102 cites W2167527173 @default.
• W1872181102 cites W2168236082 @default.
• W1872181102 cites W2168579528 @default.
• W1872181102 cites W2170928115 @default.
• W1872181102 cites W2171658624 @default.
• W1872181102 doi "https://doi.org/10.1371/journal.pone.0136324" @default.
• W1872181102 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4619590" @default.
• W1872181102 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26492353" @default.
• W1872181102 hasPublicationYear "2015" @default.
• W1872181102 type Work @default.
• W1872181102 sameAs 1872181102 @default.
• W1872181102 citedByCount "24" @default.
• W1872181102 countsByYear W18721811022015 @default.
• W1872181102 countsByYear W18721811022016 @default.
• W1872181102 countsByYear W18721811022017 @default.
• W1872181102 countsByYear W18721811022019 @default.
• W1872181102 countsByYear W18721811022020 @default.
• W1872181102 countsByYear W18721811022021 @default.
• W1872181102 countsByYear W18721811022022 @default.
• W1872181102 countsByYear W18721811022023 @default.
• W1872181102 crossrefType "journal-article" @default.
• W1872181102 hasAuthorship W1872181102A5018590706 @default.
• W1872181102 hasAuthorship W1872181102A5023531951 @default.

• next